The Use of Sensitive Chemical Antibodies for Diagnosis: Detection of Low Levels of Epcam in Breast Cancer

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Shigdar, Sarah ^a   Qian, Christine ^a,e   Lv, Li ^b   Pu, Chunwen ^c   Li, Yong ^d   Li, Lianhong ^b   Marappan, Manju ^a   Lin, Jia ^a   Wang, Lifen ^b   Duan, Wei ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c Dalian Sixth People's Hospital   (China)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Dalian Medical University ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; APTAMER DT3; APTAMER EP23; CANCER ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY 323; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY A3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PERSONALIZED MEDICINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; APTAMERS, NUCLEOTIDE; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; PARAFFIN EMBEDDING; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874548546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057613     Document Type: Article

References (45)

1. Rodriguez-Canales J, Eberle FC, Jaffe ES, Emmert-Buck MR, (2011) Why is it crucial to reintegrate pathology into cancer research? BioEssays 33: 490-498.
2. Idikio HA, (2009) Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. Int J Clin Exp Pathol 3: 169-176.
3. Stone MJ, Aronoff BE, Evans WP, Fay JW, Lieberman ZH, et al. (2003) History of the Baylor Charles A. Sammons Cancer Center. Proceedings (Baylor University Medical Center) 16: 30-58.
4. Bhatt AN, Mathur R, Farooque A, Verma A, Dwarakanath BS, (2010) Cancer biomarkers- current perspectives. Indian J Med Res 132: 129-149.
5. Lindblom A, Liljegren A, (2000) Regular review: tumour markers in malignancies. BMJ 320: 424-427.
6. Sharma S, (2009) Tumor markers in clinical practice: General principles and guidelines. Indian J Med Paediatr Oncol 30: 1-8.
7. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, et al. (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9: 16-32.
8. Patriarca C, Macchi RM, Marschner AK, Mellstedt H, (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38: 68-75.
9. Antolovic D, Galindo L, Carstens A, Rahbari N, Buchler MW, et al. (2010) Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies. BMC Biotechnol 10: 35.
10. Balzar M, Briaire-de Bruijn IH, Rees-Bakker HA, Prins FA, Helfrich W, et al. (2001) Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions. Mol Cell Biol 21: 2570-2580.
11. Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, et al. (2010) Antibody validation. Biotechniques 48: 197-209.
12. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, et al. (2011) RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102: 991-998.
13. Yeong SS, Zhu Y, Smith D, Verma C, Lim WG, et al. (2006) The last 10 amino acid residues beyond the hydrophobic motif are critical for the catalytic competence and function of protein kinase Calpha. J Biol Chem 281: 30768-30781.
14. Prang N, Preithner S, Brischwein K, Goster P, Woppel A, et al. (2005) Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 92: 342-349.
15. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV, (2003) The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 163: 2139-2148.
16. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, et al. (2005) Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 92: 1767-1772.
17. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, et al. (2000) Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60: 6281-6287.
18. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, et al. (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31: 1913-1921.
19. Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, et al. (2011) EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol 64: 415-420.
20. Cimino A, Halushka M, Illei P, Wu X, Sukumar S, et al. (2010) Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat 123: 701-708.
21. Sankpal NV, Mayfield JD, Willman MW, Fleming TP, Gillanders WE, (2011) Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Res 13: R124.
22. Gires O, Bauerle PA (2010) EpCAM as a target in cancer therapy. J Clin Oncol 28: e239-240; author reply e241-232.
23. Ellington AD, Szostak JW, (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
24. Tuerk C, Gold L, (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
25. Shigdar S, Ward AC, De A, Yang CJ, Wei M, et al. (2011) Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. Br J Haematol 155: 3-13.
26. Rayburn ER, Zhang R, (2008) Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today 13: 513-521.
27. Stoltenburg R, Reinemann C, Strehlitz B, (2007) SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 24: 381-403.
28. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, et al. (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64: 7668-7672.
29. Das M, Mohanty C, Sahoo SK, (2009) Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 6: 285-304.
30. Zeng Z, Zhang P, Zhao N, Sheehan AM, Tung CH, et al. (2010) Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues. Mod Pathol 23: 1553-1558.
31. Gupta S, Thirstrup D, Jarvis TC, Schneider DJ, Wilcox SK, et al. (2011) Rapid histochemistry using slow off-rate modified aptamers with anionic competition. Appl Immunohistochem Mol Morphol 19: 273-278.
32. Lassalle HP, Marchal S, Guillemin F, Reinhard A, Bezdetnaya L (2012) Aptamers as remarkable diagnostic and therapeutic agents in cancer treatment. Curr Drug Metab.
33. Baird GS, (2010) Where are all the aptamers? Am J Clin Pathol 134: 529-531.
34. Keefe AD, Pai S, Ellington A, (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550.
35. Wahl GM, Stern M, Stark GR, (1979) Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl-paper and rapid hybridization by using dextran sulfate. Proc Natl Acad Sci U S A 76: 3683-3687.
36. van Gijlswijk RP, Wiegant J, Raap AK, Tanke HJ, (1996) Improved localization of fluorescent tyramides for fluorescence in situ hybridization using dextran sulfate and polyvinyl alcohol. J Histochem Cytochem 44: 389-392.
37. Singh L, Jones KW, (1984) The use of heparin as a simple cost-effective means of controlling background in nucleic acid hybridization procedures. Nucleic Acids Res 12: 5627-5638.
38. Kataria S, Middha A, Sandhu P, Kapoor B, (2011) Monoclonal antibody as anti cancer agents. IJPBA 2: 1346-1356.
39. Rhodes A, Jasani B, Balaton AJ, Miller KD, (2000) Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 53: 292-301.
40. Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, et al. (2008) Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 14: 5849-5855.
41. Thurber GM, Weissleder R, (2011) Quantitating antibody uptake in vivo: conditional dependence on antigen expression levels. Mol Imaging Biol 13: 623-632.
42. Heine M, Freund B, Nielsen P, Jung C, Reimer R, et al. (2012) High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS One 7: e36258.
43. Arora R, Agarwal S, Mathur SR, Verma K, Iyer VK, et al. (2011) Utility of a limited panel of calretinin and Ber-EP4 immunocytochemistry on cytospin preparation of serous effusions: A cost-effective measure in resource-limited settings. Cytojournal 8: 14.
44. Fritschy JM, (2008) Is my antibody-staining specific? How to deal with pitfalls of immunohistochemistry. Eur J Neurosci 28: 2365-2370.
45. Gown AM, (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21Suppl 2: S8-S15.